Thursday, May 23, 2019

Oral Chelation Therapy, Diabetics And Heart Attacks

By Frances Howard

Coronary events are currently the leading cause of death among men and women. In fact, these are often the most common deaths of people in the United States. While most often coronary conditions are treated through lifestyle changes such as ceasing smoking, losing weight, lowering blood pressure, medications or surgeries, other treatments such as oral chelation therapy are on the rise.

The compound used in this therapy has not been reviewed or rated by the U. S. Food and Drug Administration. Regardless, there were over 110,000 Americans whom had previously opted for the treatment prior to a 2007 study. Ultimately, the therapy promotes a chemical process which works to bind molecules to metals and minerals.

Originally used to eliminate excess waste and toxic metals from the body, the treatment is far from new. For, EDTA has also been used to eliminate iron overload and treat lead poisoning in Western medicine. Whereas, when using the process to treat heart disease, a health care provider carefully provides injections of disodium EDTA into the veins over the course of 30 or more infusions generally on a weekly basis. After which, the treatment moves to a maintenance phase in which infusions are provided on an as needed basis.

To decipher whether or not this therapy may be effective, the National Center for Complementary and Integrative Health or NCCIH in conjunction with the National Heart, Lung and Blood Institute sponsored a trial with regards to the benefits of these infusions in individuals with a negative cardiovascular medical history. Ultimately, the trial proved that the infusions did in fact provide the most reduction in cardiovascular events, though only in individuals whom also had diabetes.

Diabetic individuals made up 1/3 of the participants in the chelation therapy group. These individuals showed a forty one percent drop in heart attacks and a forty percent risk of death from heart disease, non-fatal heart attacks or stroke. In addition, forty three percent reported a reduction in death from other causes and a fifty percent reduction in repetitive heart attacks. Whereas, non-diabetic individuals showed no significant benefits from chelation therapy.

The study also looked at individuals taking high dose minerals and vitamins along with the infusions. In most cases, the study showed that the combination provided the most reduction in risk of heart attacks versus the individuals whom were only given placebos during the trial.

Sixteen percent of individuals receiving chelation therapy and fifteen percent provided placebos during the trial halted the injections due to complications. The results included four major events, including two deaths, one death in the placebo group and one in the chelation group. To date, the most prominent side effect appears to be a burning sensation at the injection site during the infusion.

As with almost all medical studies, more research is needed before a final determination as to the success of the therapy can be made. For, these reports are from the first study ever conducted. As such, the information provided through the study does not provide enough detail to support the infusions as being a safe or effective treatment for heart attack victims.

About the Author:

No comments:

Post a Comment